Oncology Corporate Profile
9.2900 | |
0.6000 |
Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2-positive breast cancer and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation.
Website: http://www.pumabiotechnology.com/
Brand | Generic | Indication |
---|---|---|
Nerlynx™ | neratinib | Nerlynx™ is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. |
Brand / Product | Class | Area of Study | Phase | Partnership |
---|---|---|---|---|
neratinib / PB272 (+ xeloda) | tyrosine kinase inhibitor | Breast cancer | III | |
neratinib / PB272 | tyrosine kinase inhibitor | Breast cancer | III | |
neratinib / PB272 (+ torisel) | tyrosine kinase inhibitor | Breast cancer | II | |
neratinib / PB272 (+ pacitaxel) | tyrosine kinase inhibitor | Breast cancer | II | |
neratinib / PB272 | tyrosine kinase inhibitor | Various cancer types | II | |
neratinib / PB272 (+ trastuzumab emtansine) | tyrosine kinase inhibitor | Breast cancer (HER2+) | I |
View additional information on product candidates here »